Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
CogniPlus Study assessing Cognitive performance plus Physical activity in patients with Relapsing-Remitting MS under treatment with Betaferon®	Bayer	Ongoing	Betaferon	4	16036	King Fahad Hospital (Madinah), Security Forces Hospital (Riyadh), Aseer Central Hospital, King Khalid University Hospital (Riyadh), Al-Noor Specialist Hospital (Makkah), King Abdul Aziz Specialist hospital (Taif), King Fahad Specialist Hospital (Dammam)
Non transfusion dependent Thalassemia Drug Registry	Novartis	Ongoing	Exjade (Deferasirox)	4	E2422	King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Jeddah), King Khalid University Hospital (Riyadh)
A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer	Novartis	Ongoing	LEE011 (Ribociclib)	3	CLEE011E2301	King Khalid University Hospital (Riyadh)_ King Faisal Specialist Hospital and Research Center (Riyadh)
International Registry to assess mEdical Practice withlOngitudinal obseRvation for Treatment of Heart Failure(REPORT-HF)	Novartis	Ongoing	N/A	4	2401	King Fahad Specialist Hospital (Dammam)
Phase IIIb, Randomized Multicentre Comparative Trial to Evaluate the Long Term Effectiveness & Safety of the use of Carbaglu® in Patients with Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA)	KAIMRC	Ongoing	Carglumic acid	3	IIT-OE-2013-001	King Abdulaziz Medical City NG (Riyadh)_ King Fahad Medical City (Riyadh)
A Randomized, Multi-Center Study to Evaluate Cardiovascular Outcomes With ITCA 650 in Patients Treated With Standard of Care for Type 2 Diabetes	Intarcia Therapeutics	Completed	ITCA 650	3	ITCA 650-CLP-107	King Abdulaziz Medical City NG (Jeddah)_ King Abdulaziz Hospital NG (Al Ahsa)
A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer	Bayer	Ongoing	Sorafenib	3	BAY43-9006/14295	King Faisal Specialist Hospital and Research Center (Riyadh)
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis	Mast Therapeutics	Ongoing	Purified Poloxamer 188	3	MST-188-01	King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh), Maternity and Children's Hospital (Al Ahsa)_ King Fahad Medical City (Riyadh)_ King Abdulaziz University Hospital (Jeddah)
Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy and Safety of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Subjects With Congenital Fibrinogen Deficiency	Octapharma	Ongoing	Octafibrin	3	Forma 02	King Khalid University Hospital (Riyadh)
A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer	Roche	Ongoing	Pertuzumab / Trastuzumab / Taxane	3b	MO28047	King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah)